SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC - NanoViricides, Inc.
NNVC 1.155-2.9%10:39 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Straynut who wrote (12382)11/4/2019 8:45:47 PM
From: HardToFind  Read Replies (1) of 12873
 
"We have been working diligently on completing this license agreement and have taken the time to document the licensing arrangement in a professional and deliberative process, considering the related party nature of this transaction," said Mr. Stanley Glick, Chairman of the Audit Committee, adding, "We believe that this license agreement is fair to the shareholders of NanoViricides, Inc."
I call bulls--t on your statement of your belief of fairness to the shareholders. This is NOT a fair deal, nor have any to date...starting with the oldest licensing agreement we have on record, which was signed by a 70% owner of TheraCour and a 10% owner of TheraCour.

Mr. Glick, may I ask two questions:
  1. Do you own any shares of NNVC? (Yahoo! Finance seems to think not.)
  2. If not, why not?
Your actions speak louder than your words.

You do realize you have a fudiciary responsibility to act in the shareholder's interest, right? (What a cadre of liars and thieves.)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News